|
|
|
|
Newsletter - January 2021
|
|
|
|
|
|
2020 has been a successful year for LifeTime in many ways, thanks to you all! This achievement has been possible despite the unprecedented times because of the strong momentum and the spirit of our community. We hope that 2021 holds success for all of you in the endeavor you pursue to bring you the best!
|
We are so grateful to you not only for your continued partnership and support, but for also for your friendship, and we look forward to working together in the new year. We wish a happy and healthy 2021 for you and yours!
|
|
Nikolaus Rajewsky and Geneviève Almouzni
|
|
|
|
Future medicine: How to meet Europe’s disease challenges?
|
|
On 8 December 2020, LifeTime Initiative organised the online event Future medicine: How to meet Europe’s disease challenges?, gathering more than 400 participants. High-level guests from politics, science, industry and the clinics shared their vision on how digital and biomedical technologies have the capacity to transform medicine. Successful implementation of LifeTime promises to provide high-quality healthcare, strengthen Europe’s research and health industry, innovation capacity and global leadership.
|
|
|
|
|
|
How single cell-genomics could transform medicine
|
|
Simultaneous analysis of millions of individual cells could revolutionise treatments of cancer and cardiovascular, neurological, inflammatory and infectious diseases. A Science Business article.
|
|
|
|
|
|
EASI-Genomics Third call open
|
EASI-Genomics supports researchers in next-generation sequencing and other high-end genomics applications and genomic data analysis. The third call for Transnational Access is now open and is welcoming proposals from academia and industry. EASI-Genomics will provide free-of-charge sequencing and data analysis services including single-cell genomics to selected projects. Interested researchers should consult the conditions on the EASI-Genomics website and in the call text available here. The deadline for online submission is 1st of March 2021, 23:59 CET.
|
If you wish to know more, then please register for the showcasing event on 4th February 2021 by completing this Google Form. Agenda:
|
- Introduction of EASI-Genomics
- Overview of the participating facilities
- Presentation of 6 previously selected projects
- Concept of Transnational Access and other call requirements
- Q&A
|
|
|
Update from industry
|
|
|
|
New industry supporters
Berkeley Lights is a Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for its customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. The platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelectTM chips and reagent kits, advanced automation systems, and application software. The Berkeley Lights Platform aims to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for its customers throughout their cell-based product value chain.
|
|
For more information, please contact Dr. Jan Schäferkordt, Account Manager Germany at Berkeley Lights, email: jan.schaferkordt@berkelylights.com. Get latest updates from the LinkedIn page.
|
|
|
|
Bring next-generation single-cell functional
phenomics imaging platform to your lab!
Join evorion biotechnology’s “Early Adopter Program” to drive your single-cell translational and biomedical research in Medicine and Life Sciences. The exclusive offer provides hands-on training on the innovative CellCity system, enabling live-cell imaging at single-cell resolution in your lab with your samples to answer your research questions. Gain advantage of the virtual installation and full technical support during the test period. Please click here to learn more.
|
|
The program ends soon, and availability is limited, so don’t miss this opportunity to dive into the new dimension of functional phenomic analysis. Contact or schedule a quick call here.
|
|
|
|
Job openings
|
|
|
Two postdoctoral fellow positions available
at Helmholtz Zentrum München
Two postdoctoral fellow positions are available in the Schiller laboratory at Helmholtz Zentrum München in the areas of single-cell genomics & proteomics / Cell circuits in lung health and disease.
The projects will act in synergy with the lab's recent efforts to chart the cellular dynamics of mouse and human lungs for a Human Lung Cell Atlas using single-cell genomics techniques. The postdocs will develop and apply novel single-cell multi-omics methods to analyze multi-cellular signaling circuits in lung health and disease.
The lab strives to provide ground-breaking insights into cell-cell communication in lung health and disease to empower future therapeutic strategies to re-program cellular circuits in lung disease. This involves upscaling single-cell genomics readouts for high content perturbation experiments in organotypic model systems (e.g. human precision-cut lung slices) and a combination of spatial omics and imaging techniques to link localized signaling pathway inputs with gene programs and cell state identities in vivo.
|
|
Application deadline: 1 March 2021
|
|
|
|
|
|
Twelve PhD positions through the INTERCEPT-MDS Innovative Training Network
|
Twelve PhD positions are available through the INTERCEPT-MDS Innovative Training Network and hosted by the Josep Carreras Leukaemia Research Institute and 9 European partner institutions.
|
The PhD students will approach the concept of disease interception in the context of clonal myeloid diseases. They will use single-cell genomic methods to identify altered cells and test epigenetic perturbations to specifically remove them. The network is strongly aligned with the goals of the EU LifeTime Initiative. Our students will also perform collaborative research projects that include stays in other member labs and periodically meet for a joined training program. Candidates with both experimental and computational profiles are encouraged to apply.
|
INTERCEPT-MDS is coordinated by Marcus Buschbeck at the Josep Carreras Leukaemia Research Institute and our PIs are: Maria Berdasco, Manel Esteller, Hind Medyouf, Florian Grebien, Rebekka Schneider-Kramann, Torsten Haferlach, Emmet McCormack, Ana Conesa, Katharina Götze, Valeria Santini, Alex Puissant, and Raphael Itzykson.
|
|
Application deadline: 23rd February 2021
|
|
|
|
|
|
Events
|
|
The first edition of the VIB Conference Tumor heterogeneity, plasticity and therapy will take place on 5 - 6 May 2021, as a virtual conference.
Tumors are complex and evolving ecosystems composed of a wide variety of cell types, in addition to the cancer cells themselves. Increasing evidence indicates that the bi-directional interplay between tumor cells and their tumor microenvironment shape tumor evolution and therapy resistance. Within a tumor, many cancer cells differ from each other at the (epi-)genomic, transcriptional and proteomic level, as well as phenotypically and functionally. Tumor heterogeneity represents a major hurdle for therapy, which may only target a subset of tumor cells. In addition, cancer cell plasticity permits rapid adaption to therapeutics and development of tolerance and resistance, presenting additional challenges for both targeted and immunotherapies.
During this conference a range of world leaders from academia and industry will discuss the latest developments in basic research, translational and clinical research and therapeutic avenues, in the following sessions:
|
- Plasticity in initiation, progression and metastasis
- Heterogeneity and reprogramming of the tumor immune- and microenvironment
- Adaptation and resistance to targeted therapies
- Adaptation and resistance to immunotherapies
|
Abstract deadline: 12 March 2021
|
Early bird deadline: 26 March 2021
Final registration deadline: 23 April 2021
|
|
The best poster will win the Nature Poster Prize.
|
|
|
|
|
|
|
After three very successful editions, VIB presents the virtual fourth edition of this Tools & Technologies conference.
Next-generation sequencing has been and is still revolutionizing discoveries across life sciences. While established sequencing technologies are now fully embedded in the clinic and diagnostic settings, novel technological advancements spur the next revolution in sequencing technologies. These will open new avenues for research and enable new genomics insights not possible before. This conference aims to bring together experts in both established and novel sequencing technologies along with top scientists in the field.
|
The conference has two sessions on single-cell research with speakers such as:
|
- Manolis Kellis, MIT Computer Science and Artificial Intelligence Lab; Broad Institute of MIT and Harvard, the US with his talk titled: From genomics to therapeutics: single-cell dissection and manipulation of disease circuitry
- Marlon Stoeckius, Co-Director R&D Stockholm, 10X Genomics, SE
- Prisca Liberali, Friedrich Miescher Institute for Biomedical Research (FMI), CH
- Sisi Chen, California Institute of Technology, US
- Zachary Forbes, CEO, Celldom, US
- Mark D. Robinson, Department of Molecular Life Sciences, University of Zurich, CH
- Charlie Silver, CEO, Mission Bio, US
|
Abstract and early bird deadline: 29 January 2021
|
|
Final registration deadline: 26 February 2021
|
|
|
|
|
|
|
Nanoscience in Cancer Immunotherapy
The Nanoscience in Cancer Immunotherapy Workshop (NCIW), to be held in Turin from March 9-11 2021, is an international meeting jointly organized by the Università and Politecnico of Turin with the aim to provide a platform for discussion on the most recent advances in tumor immunology with a focus on nano bio-technology as a strategy to foster the impact of immunotherapy on cancer treatment.
|
|
The main goal of the NCIW is to provide a challenging transdisciplinary environment where life and nano scientists can exchange their knowledge and latest findings to accelerate and improve the coordinated progress of oncology, drug development and delivery. The program covers topics from basic research in tumor immunology to the latest advancements in the design of complex tissue models and of nanotechnology based delivery systems in cancer immunotherapy.
|
|
|
|
|
|
|
The 3rd FlyCellAtlas Meeting
The 3rd FlyCellAtlas meeting will be held in a hybrid event at MDC-BIMSB in Berlin, as well as online on April 29-30, 2021. This meeting will highlight — among other topics — recent efforts by fly labs across the globe to begin establishing a comprehensive cell atlas across tissues of the adult fruit fly. Speakers will include Jay Shendure (U. of Washington), Norbert Perrimon (Harvard) and Liqun Luo (Stanford).
|
|
The FCA was founded in 2017 and brings together Drosophila researchers aiming to explore and unravel the molecular mechanism driving Drosophila Biology from early development to homeostasis.
|
|
|
|
|
|
To make LifeTime website a platform to share news from and to our community, such as collaboration opportunities, latest science and technology updates, research calls, prizes and awards, a feed with your latest publications, events you might be organizing, or participating in as well as job openings and training opportunities, we need you contribution. Please contact the LifeTime management team and provide all the necessary information and links when applicable. We will take care of the rest.
|
We are waiting for your updates and news on:
|
- Science
- Industry
- New initiatives and calls
- Events
- Job offers
- Training opportunities
|
|
|
Follow us on Twitter @LifeTimeIni
|
|
|
|
|
|
|